MENLO
PARK, Calif., Dec. 28,
2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a
leading developer of high-quality, highly accurate sequencing
solutions, announced today that it will be participating in the
following events at the 41st Annual J.P. Morgan Healthcare
Conference:
- Panel | Multiomics: Markers for Modern Medicine on Tuesday, January 10, 2023, at approximately
5:15 PM PT.
- Company presentation and Q&A session on Wednesday, January 11, 2023, at approximately
1:30 PM PT.
The live webcasts of the events can be accessed at the company's
investors page at investor.pacificbiosciences.com. Webcast replays
will be available for at least 30 days following the
presentation.
About PacBio
Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a premier
life science technology company that is designing, developing and
manufacturing advanced sequencing solutions to help scientists and
clinical researchers resolve genetically complex problems. Our
products and technology under development stem from two highly
differentiated core technologies focused on accuracy, quality and
completeness which include our existing HiFi long read sequencing
and our emerging SBB™ short read sequencing technologies. Our
products address solutions across a broad set of research
applications including human germline sequencing, plant and animal
sciences, infectious disease and microbiology, oncology, and other
emerging applications. For more information, please visit
www.pacb.com and follow @PacBio.
Contacts
Investors:
Todd
Friedman
650.521.8450
ir@pacb.com
Media:
Lizelda Lopez
pr@pacb.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/pacbio-to-present-at-41st-annual-jp-morgan-healthcare-conference-301710738.html
SOURCE Pacific Biosciences of California, Inc.